Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

377P - Long-term survival following photodynamic therapy for malignant glioma depending on MGMT status

Date

17 Sep 2020

Session

E-Poster Display

Topics

Tumour Site

Central Nervous System Malignancies

Presenters

Artemii Rynda

Citation

Annals of Oncology (2020) 31 (suppl_4): S396-S408. 10.1016/annonc/annonc269

Authors

A. Rynda1, V. Olyushin2, D. Rostovtsev2, Y. Zabrodskaya2

Author affiliations

  • 1 Neurooncology, Almazov National Medical Research Centre-Polenov's Neurosurgical Institute - FNWMRC, 191014 - Saint-Petersburg/RU
  • 2 Neuro-oncology, Russian neurosurgical institute named after prof. A.L. Polenova, 191014 - Saint-Petersburg/RU

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 377P

Background

The aim of the study was to increase the survival rate and duration of the relapse-free period in patients with malignant brain gliomas by using photodynamic therapy as part of complex treatment.

Methods

The study included patients with glial brain tumours of supratentorial localization with a high degree of malignancy (Grade IV - glioblastoma), undergoing treatment at the Russian Neurosurgical Institute named after Prof. A.L. Polenova. The study group consisted of 50 patients and there were 50 patients in the control group. Patients in the study group were injected intravenously 1.5 hours before the operation with a photosensitizer of the chlorine E6 group (2nd generation). After resection of the tumour, a photodynamic therapy (PDT) session was performed using a Latus-2.5 laser as a radiation source. The average dose was 180 J / cm2. In the postoperative period, patients in both groups received adjuvant therapy (chemotherapy and radiation therapy). Long-term results (interrecurrence period, overall survival) were evaluated depending on the results of immunohistochemical studies (the presence of IDH mutation and MGMT).

Results

The median survival for patients with Grade IV gliomas (MGMT +) using PDT was 23.3 ± 4.1 months; in the control group (without PDT) the median survival was 16.5 ± 3.3 months (P = 0.0002). The median survival for patients with Grade IV gliomas (MGMT-) using PDT was 18.2 ± 3.5 months; in the control group (without PDT) this was 11.2 ± 2.4 months (P = 0.0001). The median duration of the inter-relapse period for patients with Grade IV gliomas (MGMT +) was 13.5 ± 2.3 months in the study group and 9.1 ± 1.4 months in the control group (P = 0.0003). The median duration of the inter-relapse period for patients with Grade IV gliomas (MGMT-) was 10.1 ± 2.2 months in the study group and 7.0 ± 1.1 months in the control group (P = 0.0001).

Conclusions

Photodynamic therapy increases the median of the inter-relapse period and life expectancy in patients with malignant gliomas. In patients expressing MGMT, the magnitude of the inter-relapse period and life expectancy was significantly higher in the group receiving PDT.

Clinical trial identification

The study was carried out in accordance with the Helsinki Declaration.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.